68: Novel therapeutic approaches to lung cancer

The present review focuses on adipocytes-released peptides known to be involved in the control of gastrointestinal motility, acting both centrally and peripherally. Thus, four peptides have been taken into account: leptin, adiponectin, nesfatin-1, and apelin. The discussion of the related physiological or pathophysiological roles, based on the most recent findings, is intended to underlie the close interactions among adipose tissue, central nervous system, and gastrointestinal tract. The better understanding of this complex network, as gastrointestinal motor responses represent peripheral signals involved in the regulation of food intake through the gut-brain axis, may also furnish a cue for the development of either novel therapeutic approaches in the treatment of obesity and eating disorders or potential diagnostic tools.

Download Full-text

Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer

Current Cancer Drug Targets ◽

10.2174/1568009617666170623123848 ◽

2018 ◽

Vol 18 (8) ◽

pp. 773-791

Author(s):

Dhaval Sanchala ◽

Lokesh K. Bhatt ◽

Kedar S. Prabhavalkar

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Driver Mutations ◽

Therapeutic Approaches ◽

Epidermal Growth ◽

Egfr Mutant

Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting 13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling has now become a regular trend in lung cancer to identify the driver mutations. Epidermal Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma. This article presents a detailed molecular insight of the therapeutic approaches for the treatment of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides concise information on relevant combinational or monotherapy clinical trials that have been completed for various approaches.

Download Full-text

Methyltransferases in the Pathogenesis of Keratinocyte Cancers

Cancers ◽

10.3390/cancers13143402 ◽

2021 ◽

Vol 13 (14) ◽

pp. 3402

Author(s):

Eun Kyung Ko ◽

Brian C. Capell

Keyword(s):

Gene Expression ◽

Squamous Cell Carcinoma ◽

Basal Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Basal Cell ◽

Histone Methylation ◽

Cutaneous Squamous Cell Carcinoma ◽

Therapeutic Approaches ◽

Novel Therapeutic

Recent evidence suggests that the disruption of gene expression by alterations in DNA, RNA, and histone methylation may be critical contributors to the pathogenesis of keratinocyte cancers (KCs), made up of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), which collectively outnumber all other human cancers combined. While it is clear that methylation modifiers are frequently dysregulated in KCs, the underlying molecular and mechanistic changes are only beginning to be understood. Intriguingly, it has recently emerged that there is extensive cross-talk amongst these distinct methylation processes. Here, we summarize and synthesize the latest findings in this space and highlight how these discoveries may uncover novel therapeutic approaches for these ubiquitous cancers.

Download Full-text

Current and Future Treatments for Classic Galactosemia

Journal of Personalized Medicine ◽

10.3390/jpm11020075 ◽

2021 ◽

Vol 11 (2) ◽

pp. 75 ◽

Cited By ~ 1

Author(s):

Britt Delnoy ◽

Ana I. Coelho ◽

Maria Estela Rubio-Gozalbo

Keyword(s):

Standard Of Care ◽

Type I ◽

Therapeutic Approaches ◽

Restricted Diet ◽

Galactose Metabolism ◽

Galt Activity ◽

Classic Galactosemia ◽

Pathogenic Factors ◽

Future Treatments ◽

Novel Therapeutic

Type I (classic) galactosemia, galactose 1-phosphate uridylyltransferase (GALT)-deficiency is a hereditary disorder of galactose metabolism. The current therapeutic standard of care, a galactose-restricted diet, is effective in treating neonatal complications but is inadequate in preventing burdensome complications. The development of several animal models of classic galactosemia that (partly) mimic the biochemical and clinical phenotypes and the resolution of the crystal structure of GALT have provided important insights; however, precise pathophysiology remains to be elucidated. Novel therapeutic approaches currently being explored focus on several of the pathogenic factors that have been described, aiming to (i) restore GALT activity, (ii) influence the cascade of events and (iii) address the clinical picture. This review attempts to provide an overview on the latest advancements in therapy approaches.

Download Full-text